Johnson & Johnson receives many interesting requests for cooperation from startup companies. Marie Tenning from J&J will give her view of what is important to think about as a start-up company in your contact with a larger company, especially from an IP perspective. What are the typical traps that a start-up has missed? Real examples will be given. The importance of having the legal issues in place and the right IP or not will be discussed and the impact thereof. Different types of cooperation forms between start-up and big company will be discussed. Finally, the advice is given in relation to real examples which have been successful historically in previous cooperation situations.
Target group: Business people with IP on their agenda
Information regarding presenters:
Marie Tenning has a Ph.D. within biotechnology and more than 10 years of experience as a scientist working for Syngenta and Danisco Biotechnology. Marie started her career as a patent attorney 1999. She has been working for 3 different IP Law Firms in Sweden, building up Life Science teams. She focused on helping small-sized companies to build up their patent portfolios to be able to license out or sell to larger companies. Since 2015 is Marie working for McNeil AB, a J&J company that is focusing on the development of OTC products.
Frida Björk is a European Patent Attorney working at the IP Law firm Awapatent AB since 1997. She has an MSc in Chemical Engineering specializing in biotechnology. She assists small and medium-sized companies to create valuable IP rights, especially patents, relevant for the companies in view of their business strategy. Frida also works for clients being based in Korea and Japan, since she has been responsible and involved in developing the business of Awapatent in those countries.
Anneli Jönsson is a European Patent Attorney working at IP Law firm Awapatent AB, which she rejoined 2017. She has an MSc in Chemical Engineering specializing in organic chemistry and biochemistry. She started her patent career as a patent examiner at the Swedish patent office 1989, and has since then also been working with creating IP rights and IP strategies at AstraZeneca, as well as at Gambro Lundia AB (today Baxter International Ltd).